Log in
Enquire now
Aphea.Bio

Aphea.Bio

A synthetic biology company making agricultural biologicals.

OverviewStructured DataIssuesContributors

Contents

aphea.bio
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Biology
Biology
Technology
Technology
Synthetic biology
Synthetic biology
Agriculture
Agriculture
Agricultural biotechnology
Agricultural biotechnology
...
Location
Belgium
Belgium
Zwijnaarde
Zwijnaarde
0
B2X
B2B
B2B
CEO
Isabel Vercauteren
Isabel Vercauteren
0
Founder
Isabel Vercauteren
Isabel Vercauteren
Pitchbook URL
pitchbook.com/profiles...179777-53
Date Incorporated
2016
Spun Out From
‌
Vlaams Instituut voor Biotechnologie
Number of Employees (Ranges)
11 – 50
Email Address
info@aphea.bio0
Full Address
Technologiepark 21 Zwijnaarde 9052 Ghent Belgium0
Investors
‌
QBIC II
PMV Capital
PMV Capital
VIVES (venture capital)
VIVES (venture capital)
V-Bio Ventures
V-Bio Ventures
Agri Investment Fund
Agri Investment Fund
Qbic Fund
Qbic Fund
Gemma Frisius Fund
Gemma Frisius Fund
Group De Ceuster
Group De Ceuster
...
Founded Date
June 26, 2017
Total Funding Amount (USD)
37,670,264
Latest Funding Round Date
2020
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Country
Belgium
Belgium

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
16,842,770

Aphea.Bio is a synthetic biology company making agricultural biologicals that is headquartered in Ghent, Belgium and was founded in 2017 by Isabel Vercauteren. The company spun out of the Vlaams Instituut voor Biotechnologie (VIB) life sciences research institute and its partner universities UGent and KU Leuven.

The companies products are synthetically made naturally occurring substances produced in nature by microorganisms and plants that improve the health and yield of crops. Aphea.Bio is focused on developing biocontrol and biostimulant products for wheat and maize using their research and development platform capable of strain identification, strain isolation, strain validation, and product development.

Funding
Series A

On June 26, 2017 Aphea.Bio completed their series A funding round with $10 million in funding from V-Bio Ventures (lead investor), PMV, Agri Investment Fund, VIVES, Qbic II, Gemma Frisius Fund KU Leuven, Group De Ceuster and Vlaams Instituut voor Biotechnologie (VIB). Part of the companies series A funding round came from a local research and development grant; €7.7 million came from investors.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Aphea.Bio

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.